Aarey Drugs & Pharmaceuticals Ltd. AI Stock Analysis
Want to see IN:AAREYDRUGS full AI Analyst Report?
Aarey Drugs & Pharmaceuticals Ltd. (AAREYDRUGS) AI Stock Analysis
Aarey Drugs & Pharmaceuticals Ltd.
(NSE:AAREYDRUGS)
The score is held back primarily by weak cash generation (recurring negative operating and free cash flow) and a high P/E valuation, while technicals are supportive with the stock trading above major moving averages and positive momentum indicators.
Aarey Drugs & Pharmaceuticals Ltd. (AAREYDRUGS) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 3.25B
- Dividend Yield
- ―
- Average Volume (3M)
- 10.25K
- Price to Earnings (P/E)
- 77.6
- Beta (1Y)
- 1.15
- Revenue Growth
- -7.69%
- EPS Growth
- -0.35%
- Country
- India
- Employees
- 132
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Aarey Drugs & Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Aarey Drugs & Pharmaceuticals Limited, founded in 1990 and headquartered in Mumbai, India, specializes in the production and distribution of a wide array of chemical substances. The company manufactures active pharmaceutical ingredients (APIs), bulk...
Aarey Drugs & Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income statement and balance sheet are acceptable (profits remain positive; leverage was moderate with equity growth), but cash flow is a major weakness: operating cash flow is frequently negative and free cash flow is consistently negative, with a sharp deterioration in 2026 alongside rising debt—raising liquidity and financing risk.
Income Statement
56NeutralBalance Sheet
62PositiveCash Flow
28Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.15B | 4.72B | 4.74B | 3.95B | 4.19B | 4.92B |
| Gross Profit | 118.62M | 141.50M | 91.32M | 132.04M | 115.07M | 195.45M |
| EBITDA | 71.58M | 132.69M | 120.64M | 114.16M | 104.50M | 140.63M |
| Net Income | 41.74M | 39.68M | 40.24M | 46.84M | 37.71M | 65.55M |
Balance Sheet | ||||||
| Total Assets | 0 | 2.97B | 2.38B | 3.03B | 2.91B | 2.45B |
| Cash, Cash Equivalents and Short-Term Investments | 33.98M | 33.98M | 32.29M | 28.90M | 11.24M | 1.92M |
| Total Debt | 0 | 499.62M | 348.56M | 313.52M | 377.18M | 141.62M |
| Total Liabilities | -1.50B | 1.47B | 997.86M | 1.71B | 1.74B | 1.32B |
| Stockholders Equity | 1.50B | 1.50B | 1.38B | 1.33B | 1.17B | 1.14B |
Cash Flow | ||||||
| Free Cash Flow | 45.49M | -233.91M | -43.10M | -37.16M | -23.25M | -66.94M |
| Operating Cash Flow | 145.98M | -109.81M | 8.95M | -29.94M | -12.81M | -44.93M |
| Investing Cash Flow | -100.49M | -124.11M | -59.39M | -17.02M | 4.41M | -32.10M |
| Financing Cash Flow | 11.69M | 233.17M | 49.24M | 55.85M | 13.54M | 22.53M |
Aarey Drugs & Pharmaceuticals Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AAREYDRUGS, the sentiment is Positive. The current price of 113.95 is above the 20-day moving average (MA) of 108.51, above the 50-day MA of 103.34, and above the 200-day MA of 84.00, indicating a bullish trend. The MACD of 2.07 indicates Negative momentum. The RSI at 61.68 is Neutral, neither overbought nor oversold. The STOCH value of 77.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:AAREYDRUGS.
Aarey Drugs & Pharmaceuticals Ltd. Peers Comparison
Overall Rating
IN:BROOKS61Neutral
IN:ALPA60Neutral
IN:MEDICAMEQ60Neutral- IN:AAREYDRUGS53Neutral
IN:MEDICO52Neutral
IN:NECLIFE44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| IN:BROOKS | 61Neutral | INR 1.99B | 2.67 | ― | ― | -14.88% | 431.30% |
| IN:ALPA | 60Neutral | INR 1.20B | 33.76 | ― | ― | 0.46% | -83.31% |
| IN:MEDICAMEQ | 60Neutral | INR 3.79B | 33.93 | ― | 0.37% | 24.66% | 10.89% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| IN:AAREYDRUGS | 53Neutral | INR 3.08B | 77.63 | ― | ― | -7.69% | -0.35% |
| IN:MEDICO | 52Neutral | INR 1.57B | 11.31 | ― | ― | 50.78% | 20.08% |
| IN:NECLIFE | 44Neutral | INR 2.01B | -0.92 | ― | ― | -99.53% | -41.93% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:AAREYDRUGS | Aarey Drugs & Pharmaceuticals Ltd. | 113.95 | 17.30 | 17.90% | |
| IN:ALPA | Alpa Laboratories Limited | 55.56 | -30.24 | -35.24% | |
| IN:BROOKS | Brooks Laboratories Limited | 65.99 | -40.91 | -38.27% | |
| IN:MEDICAMEQ | Medicamen Biotech Limited | 270.30 | -139.87 | -34.10% | |
| IN:MEDICO | Medico Remedies Ltd. | 18.89 | -34.61 | -64.69% | |
| IN:NECLIFE | Nectar Lifesciences Ltd. | 10.48 | -4.25 | -28.85% |
Aarey Drugs & Pharmaceuticals Ltd. Corporate Events
Aarey Drugs & Pharmaceuticals boosts equity base via warrant conversion
Aarey Drugs & Pharmaceuticals Ltd. operates in the pharmaceuticals and chemicals sector, manufacturing and marketing drug and chemical products while maintaining listings on the NSE and BSE under SEBI’s regulatory framework.The company’s board has ap...
Aarey Drugs & Pharmaceuticals Promoter Boosts Stake via Warrant Conversion
Aarey Drugs & Pharmaceuticals Ltd. has disclosed a change in promoter shareholding under SEBI’s Prohibition of Insider Trading Regulations. The company reported the conversion of previously issued warrants into equity shares, resulting in an updated...
Warrant Conversion Boosts Non-Promoter Stake in Aarey Drugs & Pharmaceuticals
Aarey Drugs & Pharmaceuticals Ltd. has reported a change in its shareholding structure following the conversion of previously issued warrants into equity shares by investor Nimit Rajesh Ghatalia. The company’s shares are listed on BSE Ltd. and the Na...
Aarey Drugs Promoters Boost Stake Through Warrant Conversions
Aarey Drugs & Pharmaceuticals Ltd has disclosed a material event involving the conversion of share warrants into equity shares by members of the promoter and promoter group. Following revised allotments in August and further allotments on September 3...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 06, 2026